Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Embecta Corp. Common Stock

EMBC

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Last trade $6.15
Day change -$0.10 (-1.60%)
Day range $6.03 – $6.29
Volume 274,302
Market cap $354M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$354.12M
Price / earnings
4.05×
Price / book
-0.58×
Price / sales
0.35×
EV / sales
1.6×
EV / EBITDA
6.16×

Profitability

Earnings per share
$1.54
Return on assets
6.92%
Return on equity
-14.28%
Dividend yield
7.68%

Liquidity and leverage

Debt / equity
-2.43×
Current ratio
1.68×
Quick ratio
1.17×
Cash ratio
0.51×

Cash flow

Price / cash flow
2.03×
Price / free cash flow
2.15×
Free cash flow
$164.6M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for EMBC, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$271.7M$221.8M$261.2M$264M$295.5M$259M$261.9M$286.1M
Cost of revenue$118.4M$94M$99.5M$105.5M$98.4M$94.9M$104.8M$112.3M
Gross profit$153.3M$127.8M$161.7M$158.5M$197.1M$164.1M$157.1M$173.8M
Selling, general and administrative$78.6M$76.2M$77.6M$86.9M$84.4M$79.6M$81.1M$96.8M
Research and development$5.6M$5.4M$4.6M$4.6M$4.4M$8M$20.3M$19.8M
Total operating expenses$104.6M$92.8M$82.2M$102M$103.1M$101.2M$101.4M$147.6M
Operating income$48.7M$35M$79.5M$56.5M$94M$62.9M$55.7M$26.2M
Interest expense-$23.9M-$22.6M$0$0-$26.6M-$26.7M$0$0
Income before taxes$27.6M$9.5M$58.9M$29M$72.2M$35.8M-$700K-$7M
Income taxes$6.5M$13.6M$14.8M$2.6M$26.7M$12.3M-$700K-$21.6M
Net income$21.1M-$4.1M$44.1M$26.4M$45.5M$23.5M$0$14.6M
Net income attributable to common shareholders$21.1M-$4.1M$44.1M$26.4M$45.5M$23.5M$0$14.6M
EBITDA$67.1M$45.2M$89.8M$61.8M$111M$71.9M$65.1M$31.9M
Basic earnings per share$0.36-$0.07$0.75$0.45$0.78$0.40$0.00$0.25
Diluted earnings per share$0.36-$0.07$0.74$0.44$0.78$0.40$0.00$0.24

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

Law firm Bernstein Liebhard announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. The firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. Current shareholders who purchased shares before November 25, 2025 are encouraged to contact the firm regarding their legal rights.

GlobeNewswire Inc.

embecta to Participate in Investor Events

Embecta Corp. (EMBC) announced that management will participate in investor events at the Wells Fargo 2026 Healthcare Conference on September 9, 2026, in Boston and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026 on September 10, 2026, where they will host fireside chats and one-on-one investor meetings.

GlobeNewswire Inc.

EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for investors to participate.

GlobeNewswire Inc.

ZILLOW DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Zillow Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - Z, ZG

Rosen Law Firm is reminding investors in Zillow Group, Embecta Corp, and GoDaddy Inc. of upcoming lead plaintiff deadlines in securities class actions. The Zillow lawsuit alleges the company made false statements regarding its Redfin agreement and antitrust risks. Investors with losses exceeding $100K are encouraged to contact the firm before the respective deadlines.

GlobeNewswire Inc.

Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results

Embecta Corp. (NASDAQ: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced its third quarter fiscal 2026 financial results on August 7, 2026. The company hosted a conference call and webcast for analysts and investors to discuss the earnings.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Aug 27, 2026$0.01Sep 15, 2026recurring
May 28, 2026$0.01Jun 15, 2026recurring
Feb 27, 2026$0.15Mar 17, 2026recurring
Dec 5, 2025$0.15Dec 18, 2025recurring
Aug 29, 2025$0.15Sep 15, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.